The contributions of this paper can be summarized as follows: TMP might treat ALI/ARDS patients by reducing the pulmonary inflammation in a mechanism of inhibiting TLR4/TRAF/NFκB/NLRP3/caspase-1 and TLR4/caspase-8/caspase-3 signaling pathways in macrophages and reversing the polarization of macrophages from M1 to M2 to reduce cell pyroptosis and inflammatory response activated by NFκB. Here, NLRP3 is linked to acute respiratory distress syndrome.